Cardiovascular Research Journal Impact Factor & Information

Publisher: British Medical Association; British Cardiac Society; European Society of Cardiology, Oxford University Press (OUP)

Journal description

Cardiovascular Research is the International Basic Science Journal of the European Society of Cardiology. The Journal is concerned with both basic and clinical research in the field of cardiovascular physiology and pathophysiology. The Journal welcomes submission of papers both at the molecular, subcellular, cellular, organ and organism level, and of clinically oriented papers offering insight into (patho)physiological mechanisms.

Current impact factor: 5.81

Impact Factor Rankings

2015 Impact Factor Available summer 2015
2013 / 2014 Impact Factor 5.808
2012 Impact Factor 5.94
2011 Impact Factor 6.064
2010 Impact Factor 6.051
2009 Impact Factor 5.801
2008 Impact Factor 5.947
2006 Impact Factor 5.826
2005 Impact Factor 5.283
2004 Impact Factor 4.575
2003 Impact Factor 5.164
2002 Impact Factor 4.692
2001 Impact Factor 4.552
2000 Impact Factor 3.783
1999 Impact Factor 3.092
1998 Impact Factor 2.996
1997 Impact Factor 2.885
1996 Impact Factor 3.263
1995 Impact Factor 3.494
1994 Impact Factor 2.89
1993 Impact Factor 2.087
1992 Impact Factor 1.476

Impact factor over time

Impact factor
Year

Additional details

5-year impact 6.11
Cited half-life 7.00
Immediacy index 1.69
Eigenfactor 0.05
Article influence 1.93
Website Cardiovascular Research website
Other titles Cardiovascular research, CVR
ISSN 0008-6363
OCLC 1553351
Material type Periodical, Internet resource
Document type Journal / Magazine / Newspaper, Internet Resource

Publisher details

Oxford University Press (OUP)

  • Pre-print
    • Author can archive a pre-print version
  • Post-print
    • Author cannot archive a post-print version
  • Restrictions
    • 12 months embargo
  • Conditions
    • Pre-print can only be posted prior to acceptance
    • Pre-print must be accompanied by set statement (see link)
    • Pre-print must not be replaced with post-print, instead a link to published version with amended set statement should be made
    • Pre-print on author's personal website, employer website, free public server or pre-prints in subject area
    • Post-print in Institutional repositories or Central repositories
    • Publisher's version/PDF cannot be used
    • Published source must be acknowledged
    • Must link to publisher version
    • Set phrase to accompany archived copy (see policy)
    • Eligible authors may deposit in OpenDepot
    • The publisher will deposit in PubMed Central on behalf of NIH authors
    • Publisher last contacted on 19/02/2015
    • This policy is an exception to the default policies of 'Oxford University Press (OUP)'
  • Classification
    ​ yellow

Publications in this journal

  • [Show abstract] [Hide abstract]
    ABSTRACT: Aims Growing evidence links microRNA to the process of peripheral vascular disease. Recently, we have found microRNA-1298(miR-1298) is one of the most significantly downregulated microRNAs in human arteries with arteriosclerosis obliterans (ASO) of the lower extremities. However, little is known regarding its role in the process of ASO. The present study aimed to investigate the expression, regulatory mechanisms, and functions of miR-1298 in the process of ASO.Methods and results Using quantitative reverse-transcription polymerase chain reaction and in situ hybridization assays, miR-1298 was observed predominantly expressed in the vascular smooth muscle cells (VSMCs) and was significantly downregulated in ASO compared with normal arteries. Pyrosequencing analysis revealed that the miR-1298 DNA upstream CpG sites were hypermethylated in ASO compared with normal arteries. Next, the luciferase reporter assay revealed that miR-1298 downregulation is related with upstream DNA CpG site hypermethylation. Introducing a miR-1298 mimic into cultured VSMCs significantly attenuated cell proliferation and migration. Connexin 43 (Cx43) was validated to be a functional target of miR-1298 that was involved in the miR-1298-mediated cellular effects. Finally, lentivirus-mediated delivery of miR-1298 and its target Cx43 into a rat carotid balloon injury model indicated that re-overexpression of miR-1298 significantly decreased neointimal formation by targeting connexin 43.Conclusions Our data demonstrate a specific role of the upstream DNA methylation/miR-1298/Cx43 pathway in regulating VSMC function and suggest that modulation of miR-1298 levels may offer a novel therapeutic approach for ASO.
    Cardiovascular Research 09/2015; DOI:10.1093/cvr/cvv160
  • [Show abstract] [Hide abstract]
    ABSTRACT: sec> Aims Remote ischaemic conditioning (RIC) has been shown to reduce myocardial infarct size in patients. Our objective was to investigate whether the combination of RIC with either exenatide or glucose–insulin–potassium (GIK) is more effective than RIC alone. Methods and results Pigs were submitted to 40 min of coronary occlusion followed by reperfusion, and received (i) no treatment, (ii) one of the following treatments: RIC (5 min ischemia/5 min reperfusion × 4), GIK, or exenatide (at doses reducing infarct size in clinical trials), or (iii) a combination of two of these treatments (RIC + GIK or RIC + exenatide). After 5 min of reperfusion ( n = 4/group), prominent phosphorylation of Akt and endothelial nitric oxide synthase (eNOS) was observed, both in control and reperfused myocardium, in animals receiving GIK, and mitochondria from these hearts showed reduced ADP-stimulated respiration. 1H NMR-based metabonomics disclosed a shift towards increased glycolysis in GIK and exenatide groups. In contrast, oxidative stress (myocardial nitrotyrosine levels) and eNOS uncoupling were significantly reduced only by RIC. In additional experiments ( n = 7–10/group), ANOVA demonstrated a significant effect of the number of treatments after 2 h of reperfusion on infarct size (triphenyltetrazolium, % of the area at risk; 59.21 ± 3.34, 36.64 ± 3.03, and 21.04 ± 2.38% for none, one, and two treatments, respectively), and significant differences between one and two treatments ( P = 0.004) but not among individual treatments or between RIC + GIK and RIC + exenatide. Conclusions GIK and exenatide activate cardioprotective pathways different from those of RIC, and have additive effects with RIC on infarct size reduction in pigs. </sec
    Cardiovascular Research 07/2015; 107(2). DOI:10.1093/cvr/cvv171
  • [Show abstract] [Hide abstract]
    ABSTRACT: Aims Previously we demonstrated that both hypoxia inducible factor 1 (HIF-1) and bone morphogenetic protein 4 (BMP4) up-regulate transient receptor potential canonical (TRPC) 1 and TRPC6, resulting in increased basal intracellular Ca2+ concentration ([Ca2+]i) in pulmonary arterial smooth muscle cells (PASMCs), driving development of chronic hypoxia-induced pulmonary hypertension (CHPH). This study aims to determine whether HIF-1 regulates BMP4, and whether BMP4 mediates TRPC and basal [Ca2+]i increases in hypoxic PASMCs.
    Cardiovascular Research 07/2015; 107(1). DOI:10.1093/cvr/cvv122
  • [Show abstract] [Hide abstract]
    ABSTRACT: Cardiovasc Res. 2015 May 20. pii: cvv141. [Epub ahead of print] Down-Regulation of miR-23b Induces Phenotypic Switching of Vascular Smooth Muscle Cells in vitro and in vivo. Iaconetti C1, De Rosa S1, Polimeni A1, Sorrentino S1, Gareri C1, Carino A1, Sabatino J1, Colangelo M1, Curcio A1, Indolfi C2. Author information Abstract AIMS: Phenotypic switch of vascular smooth muscle cells (VSMCs) plays a key role in the pathogenesis of different vascular diseases, such as atherosclerosis and restenosis after coronary intervention. microRNAs have been identified as key regulators of VSMCs biology. The miR-23b is highly expressed in VSMCs and it is involved in differentation, proliferation and migration of several non-vascular cell types. However, the role of miR-23b in vascular disease is currently unknown. Thus, the aim of the present study was to evaluate the role of miR-23b on VSMCs phenotypic switch in vitro and after vascular injury in vivo. METHODS AND RESULTS: To determine the changes of miR-23b expression in injured arterial wall, we used the standard rat carotid artery balloon injury model. In vivo studies demonstrated that miR-23b is downregulated after vascular injury. Gain of function studies showed that overexpression of miR-23b inhibited VSMCs proliferation and migration whereas the opposite effect was obtained with the in vitro inhibition of miR-23b. We further demonstrated that miR-23b can significantly promote the expression of VSMCs marker genes such as ACTA2 and MYH11. Overexpression of miR-23b in balloon-injured arteries by Ad-miR-23b markedly decreased neointimal hyperplasia. Finally, miR-23b specifically suppresses urokinase-type plasminogen activator (uPA), SMAD3 and transcription factor forkhead box O4 (FoxO4) expression in phenotypically modulated VSMCs. By luciferase reporter assay, we validated the transcription factor FoxO4 as a direct target of miR-23b in VSMCs. CONCLUSIONS: We identify miR-23b as a novel regulator of VSMCs phenotypic switch in vitro and following vascular injury in vivo.
    Cardiovascular Research 05/2015; 2015 May 20. pii: cvv141. [Epub ahead of print].
  • [Show abstract] [Hide abstract]
    ABSTRACT: Aims Cardiac aging involves the progressive development of cardiac fibrosis and diastolic dysfunction coordinated by matrix metalloproteinase (MMP)-9. Here, we report a cardiac aging signature that encompasses macrophage pro-inflammatory signaling in the left ventricle (LV) and distinguishes biological from chronological aging.
    Cardiovascular Research 05/2015; 106(3). DOI:10.1093/cvr/cvv128
  • [Show abstract] [Hide abstract]
    ABSTRACT: Aims Pro-inflammatory response of VSMCs is triggered by endothelial damage and a causative step for thrombosis and neointimal thickening in the injured arterial vessels. Therefore, we investigate a role of cytosolic Hsp60 as a novel pro-inflammatory mediator in VSMCs.
    Cardiovascular Research 05/2015; 106(3). DOI:10.1093/cvr/cvv130
  • [Show abstract] [Hide abstract]
    ABSTRACT: Atherosclerosis manifests itself as arterial plaques, which lead to heart attacks or stroke. Treatments supporting plaque regression are therefore aggressively pursued. Studies conducted in models in which hypercholesterolemia is reversible, such as the Reversa mouse model we have employed in the current studies, will be instrumental for the development of such interventions. Using this model we have shown that advanced atherosclerosis regression occurs when lipid lowering is used in combination with bone marrow endothelial progenitor cell (EPC) treatment. However, it remains unclear how EPCs home to regressing plaques and how they augment atherosclerosis reversal. Here we identify molecules that support functional responses of EPCs during plaque resolution. Chemokines CXCL1 and CX3CL1 were detected in the vascular wall of atheroregressing Reversa mice, and their cognate receptors CXCR2 and CX3CR1 were observed on adoptively transferred EPCs in circulation. We tested whether CXCL1-CXCR2 and CX3CL1-CX3CR1 axes regulate functional responses of EPCs during plaque reversal. We show that pharmacologic inhibition of CXCR2 or CX3CR1, or genetic inactivation of these two chemokine receptors interfered with EPC-mediated advanced atherosclerosis regression. We also demonstrate that CXCR2 directs EPCs to regressing plaques while CX3CR1 controls a paracrine function(s) of these cells. CXCR2 and CX3CR1 differentially regulate EPC functional responses during atheroregression. Our study improves understanding of how chemokines and chemokine receptors regulate plaque resolution, which could determine the effectiveness of interventions reducing complications of atherosclerosis. Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2015. For permissions please email: journals.permissions@oup.com.
    Cardiovascular Research 03/2015; 106(2). DOI:10.1093/cvr/cvv111
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Peptidyl-prolyl cis-trans-isomerases are a highly conserved family of immunophilins. The three peptidyl-prolyl cis-trans-isomerase subfamilies are cyclophilins, FK-506 binding proteins and parvulins. Peptidyl-prolyl cis-trans-isomerases are expressed in multiple human tissues and regulate different cellular functions e.g. calcium handling, protein folding and gene expression. Moreover, these subfamilies have been shown to be consistently involved in several cardiac and vascular diseases including heart failure, arrhythmias, vascular stenosis, endothelial dysfunction, atherosclerosis and hypertension. This review provides a concise description of the peptidyl-prolyl cis-trans-isomerases and presents an incisive selection of studies focused on their relationship with cardiovascular diseases. Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2015. For permissions please email: journals.permissions@oup.com.
    Cardiovascular Research 03/2015; 106(3). DOI:10.1093/cvr/cvv096